Ventripoint Diagnostics Ltd. (VPTDF) 0.0405 $VPTDF
Latest Clinical Study Finds Ventripoint VMS(TM) Offers Consistent and Accurate Results Regardless of Examiner
Marketwired - Mon Apr 27, 7:54AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that a group led by Dr. Daniel Knight in London, United Kingdom, has demonstrated further the accuracy of Ventripoint's VMS(TM) heart analysis system.
VPT.VN: 0.055 (unch)
Ventripoint Announces Response to Interactive Review for Recent 510(k) Submission to FDA
Marketwired - Wed Apr 08, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has completed the first round of review concerning the most recent 510(k) submission to the U.S. Food & Drug Administration ("FDA". On March 26th, 2015, Ventripoint received a request for additional information via Interactive Review. The Company responded promptly and delivered the requested information to the FDA for evaluation.
VPT.VN: 0.055 (unch)
Ventripoint Announces Distribution Partner for Military and VA Medical Centers
Marketwired - Mon Mar 30, 7:34AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation" (TSX VENTURE: VPT) is pleased to announce that is has appointed PYP Enterprises LLC (PYP) to be the exclusive distributor to the US military hospitals including the VA hospitals.
VPT.VN: 0.055 (unch)
Ventripoint Announces Acceptance Notification From US-FDA of Recent 510(k) Submission
Marketwired - Fri Mar 27, 7:01AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE: VPT) is pleased to announce that it has received Acceptance Review Notification concerning the Company's recent 510(k) submission (see news release March 16, 2015) to the U.S. Food & Drug Administration ("US-FDA". The Notification confirms that the submission contains all of the necessary elements and information needed to proceed with the substantive review. A lead reviewer has been assigned and the substantive review has begun. The US-FDA guidelines mandate that the Company receive its first communication regarding the submission within 60 days, with closure of the submission expected to occur within 90 days.
VPT.VN: 0.055 (unch)
Ventripoint Announces Resignation of Director
Marketwired - Wed Mar 25, 6:26AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that Mr. Brad Harlow has resigned from the Board of Directors of the Company to focus on his duties as CEO of Cardiac Insight Inc. He is also continuing as President & CEO of PhysioSonics Inc. These companies, plus his work with CBC Partners LLC, a lending company, are eclipsing the time needed as a Director at Ventripoint. The Company wishes him success in the future and thanks him for his over 4 years of excellent service and dedication to governance of the Company.
VPT.VN: 0.055 (unch)
Ventripoint Applies to U.S. FDA to Expand Use of the VMS Heart Analysis System to all Types of Heart Disease
Marketwired - Mon Mar 16, 7:17AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has recently filed an additional submission for 510(k) clearance to the U.S. Food & Drug Administration (FDA).
VPT.VN: 0.055 (unch)
Ventripoint Announces Completion of Initial Establishment Inspection by FDA
Marketwired - Tue Jan 13, 3:00PM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has completed an initial Establishment Inspection by the U.S. Food and Drug Administration (FDA) on January 8, 2015. This initial Establishment Inspection following 510(k) clearance of the Ventripoint Medical System in March, 2014, was started on December 29, 2014 at the Company's Bellevue, Washington location. It was a pre-announced Good Manufacturing Practices (GMP) facility inspection. "This was a very detailed inspection of our Quality System as it relates to Federal Regulations," stated Jeff Jellum, Director of Operations. The inspection reported only two observations as noted on FDA Form 483. "While we strive for perfection, we are pleased to have only two minor items that are easily addressed following our first FDA inspection."
VPT.VN: 0.055 (unch)
First Patients Examined with Ventripoint's Heart Analysis System in China at Shandong Provincial Hospital
Marketwired - Thu Dec 18, 6:27AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has installed its VMS(TM) heart analysis system at the Shandong Provincial Hospital (SPH) in Jinan, China and has examined a number of patients. The SPH does 300 cardiac ultrasound exams a day and has nine other hospitals in its group.
VPT.VN: 0.055 (unch)
Ventripoint Appoints Dr. Alan Rabinowitz to Board of Directors
Marketwired - Thu Dec 04, 7:03AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce the appointment of Dr. Alan Rabinowitz to the Board of Directors.
VPT.VN: 0.055 (unch)
Ventripoint Heart Analysis System to be Exhibited at International Medical Conference in Vienna, Austria, and Grant of Stock Options
Marketwired - Wed Dec 03, 6:43AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that the Company will be exhibiting at the EuroEcho-Imaging 2014 Congress from December 3-6, 2014. More than 3,500 participants who focus on echocardiology are expected to attend EuroEcho-Imaging 2014, which is the official annual meeting of the European Association of Cardiovascular Imaging, a registered branch of the European Society of Cardiology. Held in cooperation with the Austrian Working Group of Echocardiography, the Congress takes place in Vienna, Austria, at the Reed Messe Wien GmbH Congress Center.
VPT.VN: 0.055 (unch)
Latest Clinical Study Finds Ventripoint VMS(TM) Offers Consistent and Accurate Results Regardless of Examiner
Marketwired - Mon Apr 27, 7:54AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that a group led by Dr. Daniel Knight in London, United Kingdom, has demonstrated further the accuracy of Ventripoint's VMS(TM) heart analysis system. VPT.VN: 0.055 (unch)
Ventripoint Announces Response to Interactive Review for Recent 510(k) Submission to FDA
Marketwired - Wed Apr 08, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has completed the first round of review concerning the most recent 510(k) submission to the U.S. Food & Drug Administration ("FDA". On March 26th, 2015, Ventripoint received a request for additional information via Interactive Review. The Company responded promptly and delivered the requested information to the FDA for evaluation. VPT.VN: 0.055 (unch)
Ventripoint Announces Distribution Partner for Military and VA Medical Centers
Marketwired - Mon Mar 30, 7:34AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation"
(TSX VENTURE: VPT) is pleased to announce that is has appointed PYP Enterprises LLC (PYP) to be the exclusive distributor to the US military hospitals including the VA hospitals. VPT.VN: 0.055 (unch)
Ventripoint Announces Acceptance Notification From US-FDA of Recent 510(k) Submission
Marketwired - Fri Mar 27, 7:01AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"
(TSX VENTURE: VPT) is pleased to announce that it has received Acceptance Review Notification concerning the Company's recent 510(k) submission (see news release March 16, 2015) to the U.S. Food & Drug Administration ("US-FDA". The Notification confirms that the submission contains all of the necessary elements and information needed to proceed with the substantive review. A lead reviewer has been assigned and the substantive review has begun. The US-FDA guidelines mandate that the Company receive its first communication regarding the submission within 60 days, with closure of the submission expected to occur within 90 days. VPT.VN: 0.055 (unch)
Ventripoint Announces Resignation of Director
Marketwired - Wed Mar 25, 6:26AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that Mr. Brad Harlow has resigned from the Board of Directors of the Company to focus on his duties as CEO of Cardiac Insight Inc. He is also continuing as President & CEO of PhysioSonics Inc. These companies, plus his work with CBC Partners LLC, a lending company, are eclipsing the time needed as a Director at Ventripoint. The Company wishes him success in the future and thanks him for his over 4 years of excellent service and dedication to governance of the Company. VPT.VN: 0.055 (unch)
Ventripoint Applies to U.S. FDA to Expand Use of the VMS Heart Analysis System to all Types of Heart Disease
Marketwired - Mon Mar 16, 7:17AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has recently filed an additional submission for 510(k) clearance to the U.S. Food & Drug Administration (FDA). VPT.VN: 0.055 (unch)
Ventripoint Announces Completion of Initial Establishment Inspection by FDA
Marketwired - Tue Jan 13, 3:00PM CST
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has completed an initial Establishment Inspection by the U.S. Food and Drug Administration (FDA) on January 8, 2015. This initial Establishment Inspection following 510(k) clearance of the Ventripoint Medical System in March, 2014, was started on December 29, 2014 at the Company's Bellevue, Washington location. It was a pre-announced Good Manufacturing Practices (GMP) facility inspection. "This was a very detailed inspection of our Quality System as it relates to Federal Regulations," stated Jeff Jellum, Director of Operations. The inspection reported only two observations as noted on FDA Form 483. "While we strive for perfection, we are pleased to have only two minor items that are easily addressed following our first FDA inspection." VPT.VN: 0.055 (unch)
First Patients Examined with Ventripoint's Heart Analysis System in China at Shandong Provincial Hospital
Marketwired - Thu Dec 18, 6:27AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has installed its VMS(TM) heart analysis system at the Shandong Provincial Hospital (SPH) in Jinan, China and has examined a number of patients. The SPH does 300 cardiac ultrasound exams a day and has nine other hospitals in its group. VPT.VN: 0.055 (unch)
Ventripoint Appoints Dr. Alan Rabinowitz to Board of Directors
Marketwired - Thu Dec 04, 7:03AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce the appointment of Dr. Alan Rabinowitz to the Board of Directors. VPT.VN: 0.055 (unch)
Ventripoint Heart Analysis System to be Exhibited at International Medical Conference in Vienna, Austria, and Grant of Stock Options
Marketwired - Wed Dec 03, 6:43AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that the Company will be exhibiting at the EuroEcho-Imaging 2014 Congress from December 3-6, 2014. More than 3,500 participants who focus on echocardiology are expected to attend EuroEcho-Imaging 2014, which is the official annual meeting of the European Association of Cardiovascular Imaging, a registered branch of the European Society of Cardiology. Held in cooperation with the Austrian Working Group of Echocardiography, the Congress takes place in Vienna, Austria, at the Reed Messe Wien GmbH Congress Center. VPT.VN: 0.055 (unch)
